Neurocrine Biosciences has commenced the Phase I clinical trial of its oral, small molecule vesicular monoamine transporter 2 (VMAT2) inhibitor, NBI-1140675 in healthy adults. The trial aims to assess ...

The "Tourette Syndrome Drugs Market Outlook 2026-2034: Market Share, and Growth Analysis" has been added to ResearchAndMarkets.com's offering.The Tourette Syndrome Drugs Market is projected to witness ...

Experts and guidelines recommend vesicular monoamine 2 transporter (VMAT2) inhibitors as the best option for treating more severe cases of tardive dyskinesia, an involuntary movement disorder caused ...

announced today that it has successfully completed a second Phase I clinical trial of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The positive results of this Phase I study ...

SAN DIEGO, March 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics ...

On October 1, 2012, Neurocrine Bio (NASDAQ:NBIX) announced it had initiated a phase IIb clinical trial with its proprietary Vesicular Mono-Amine Transporter 2 (VMAT-2) inhibitor, NBI-98854. The phase ...

A 36-year-old man with a diagnosis of schizophrenia, according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), was referred to a psychiatry clinic for severe, ...

Neurotransmitters are a class of signaling chemicals, including monoamines such as serotonin, dopamine, and histamine, which play a vital role in a variety of neurological activities, including mood, ...

SAN DIEGO, May 23, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the initial Phase II Tourette syndrome T-Force GREEN study of INGREZZA ® (valbenazine), a small ...

In 2024, several research and pharmacological advancements were made for tardive dyskinesia, a movement disorder caused by dopamine-blocking medications. Below are some of the highlights of the year.